Development and Validation of Stability-Indicating Assay Method by RP-HPLC for Simultaneous Estimation of Rosuvastatin Calcium and Fenofibrate in Pharmaceutical Dosage Form

Pimpale Awdhut and Kakde Rajendra*
Department of Pharmaceutical Sciences, R. T. M. Nagpur University, Amravati Road, Nagpur – 440033, Maharashtra, India

ABSTRACT

A simple, precise, and accurate stability-indicating reversed-phase high-performance liquid chromatography method has been established for the simultaneous estimation of rosuvastatin calcium and fenofibrate in combined bulk and tablet formulation. The chromatographic separation was performed on reverse phase Princeton (C18) (250 mm x 4.6 mm, 5µ) column with mobile phase as a mixture of water (pH adjusted to 3.0 with orthophosphoric acid) and acetonitrile in the ratio (40:60) v/v at the flow rate 1.0 ml/min. Detection was carried out at wavelength 240 nm. The retention time under the optimized condition of Rosuvastatin calcium and Fenofibrate was found to be 2.485 & 3.905 minutes respectively. The calibration curve was linear in the range of 6-16 µg/ml and 87-232 µg/ml for rosuvastatin calcium and fenofibrate with a correlation coefficient of 0.9999 and 0.9994 respectively. Relative standard deviation values for all key parameters were less than 2.0%. The percentage recovery was found to be 99.66-100.37% and 99.13-100.44% for rosuvastatin calcium and fenofibrate respectively. The developed reversed-phase high-performance liquid chromatography method was found to be simple, specific, sensitive, rapid, linear, accurate, precise, and economical, and could be used for regular quality control of rosuvastatin calcium and fenofibrate in bulk and tablet formulations.

Keywords: Rosuvastatin calcium, Fenofibrate, RP-HPLC, Method validation, ICH guidelines.

INTRODUCTION

Rosuvastatin calcium (RSV), is chemically (3R,5S,6E)-7-{4-[(4-fluorophenyl)-6-(1-methylene)-2[methyl-(methyl sulphonyl amino)]-5pyrimidinyl}-3,5-dihydroxy-6-heptenoic acid calcium (Fig. 1). It is a synthetic lipid-lowering agent that blocks the production of cholesterol in the body, it is a competitive 3-hydroxy-3-methyl-glutaryl coenzyme-A reductase inhibitor effective in lowering LDL cholesterol and triglycerides, developed for the treatment of dyslipidemia 1-2. Fenofibrate (FEN), is chemically propan-2-yl 2-{4-[(4-chlorophenyl) carbonyl] phenox} methyl propanoate (Fig. 2). It is mainly used to decrease cholesterol levels in patients at risk of cardiovascular disease. Like other fibrates, it reduces low-density, lipoprotein (LDL) and very-low-density lipoprotein (VLDL) levels, as well as increasing high-density lipoprotein (HDL) levels and reducing triglycerides levels. The drug is white to white-off powder, solubile in dimethylformamide, dimethyl sulfoxide, acetone, acetonitrile slightly soluble in water and methanol 3-5. An extensive literature survey revealed that several HPLC should be methods were reported for the estimation of rosuvastatin calcium and fenofibrate in bulk and tablet formulation 6-17, The International Conference on Harmonization (ICH) guideline entitled “Stability testing of new drug substances and products” requires that stress testing be administered to elucidate the inherent stability characteristics of the active substance 18, An ideal stability-indicating technique is one that resolves the drug, and its degradation products efficiently. Consequently, the implementation of an analytical methodology to work out RSV and FEN, in the presence of its degradation products is sort of a challenge for pharmaceutical analysts. Therefore, it was thought necessary to study the stability of RSV and FEN under acidic, alkaline, hydrolytic, oxidative, light, and thermal conditions. The reported method has the drawbacks of long runtime and less economical with a high proportion of organic phase. Hence, an attempt was made to develop reversed-phase high-performance liquid chromatography (RP-HPLC) which is a simple, rapid, accurate, precise, specific, economical, and sensitive method for the estimation of rosuvastatin calcium and fenofibrate in combined bulk and tablet dosage form.
Preparation of standard solution of RSV and FEN

For RSV, an accurately weighed 1.0 mg of RSV was transferred to a 10.0 ml volumetric flask and dissolved in 5.0 ml of diluent. The volume was completed to 10.0 ml with diluent. One milliliter of the resulting solution was pipetted in 10.0 ml volumetric flask and the volume was made up to 10.0 ml with diluent to furnish a solution of concentration 10 μg/ml of RSV.

For FEN, an accurately weighed 14.5 mg of FEN was transferred to a 10.0 ml volumetric flask and dissolved in 5.0 ml of diluent. The volume was completed to 10.0 ml with diluent. One milliliter of the resulting solution was pipetted in 10.0 ml volumetric flask and the volume was made up to 10.0 ml with diluent to furnish a solution of concentration 145 μg/ml of FEN.

For the working mixed standard solution, an accurately weighed 1.0 mg of RSV and 14.5 mg of FEN were transferred to a 10.0 ml volumetric flask and dissolved in 5.0 ml of diluent. The volume was completed to 10.0 ml with diluent. One milliliter of the resulting solution was pipetted in 10.0 ml volumetric flask and the volume was made up to 10.0 ml with diluent to furnish a solution of concentration 10 μg/ml and 145 μg/ml of RSV and FEN respectively.

Preparation of sample solution of RSV and FEN

Twenty tablets were weighed and finely powdered. An accurately weighed amount of powder equivalent to 1.0 mg of RSV and 14.5 mg of FEN was transferred into a 10.0 ml volumetric flask. Then 5.0 ml of diluent was added in it. The flask contents were sonicated for 10 min to make the contents homogeneous. This solution was then diluted up to the mark with diluent. The resultant solution was filtered through Whatman Grade I filter paper. One milliliter of the filtrate was transferred to a 10 ml volumetric flask and then the volume was made up to 10 ml with diluent to furnish a solution containing 10 μg/ml of RSV and 145 μg/ml of FEN. Six replicate of tablet powder equivalent to 1.0 mg of RSV and 14.5 mg of FEN were transferred into six 10.0 ml volumetric flask and homogeneous sample solutions were prepared similarly.

Method Validation

The developed method was validated following ICH guidelines (ICH Q2R1) for accuracy, precision, specificity, linearity, limit of detection (LOD), limit of quantification (LOQ), robustness 19.

Table 1: Optimized chromatographic condition

| Chromatographic condition          | Mobile phase                        | Flow rate | Column                  | Detector wavelength | Column temperature | Injection volume | Runtime | Diluent         | Retention time |
|-----------------------------------|-------------------------------------|-----------|-------------------------|---------------------|--------------------|------------------|---------|-----------------|----------------|
|                                   | Water (pH adjusted to 3.0 with ortho phosphoric acid): Acetonitrile (40:60) v/v | 1.0 ml/min | Princeton C18 (250 mm × 4.6 mm, 5 μ) | 240 nm              | 30 °C              | 10 μl          | 20 minutes | Acetonitrile:Water (50:50) | About 2.485 minutes for Rosuvastatin calcium peak & 3.905 minutes for Fenofibrate peak |

MATERIALS AND METHODS

Chemicals and Reagents

Pharmaceutical grade Rosuvastatin Calcium and Fenofibrate were procured as a gift sample from Cadila Pharmaceuticals Ltd., Ahmedabad (India), Zyrova F-10 a tablet formulation, obtained commercially.

Acetonitrile, methanol, orthophosphoric acid, hydrochloric acid, sodium hydroxide, and hydrogen peroxide 30% of analytical grade were used throughout the work.

Instrumentation

Shimadzu HPLC system and PDA detector with Lab Solution software were used.

Chromatographic Conditions

Chromatographic separation was achieved on a reverse-phase column Princeton C18 (250 mm × 4.6 mm, 5 μ) at ambient temperature using a mobile phase consisting of a mixture of buffer (pH 3.0, adjusted with orthophosphoric acid) and acetonitrile in the ratio of (40:60) v/v at a flow rate of 1.0 ml/min. Detection was carried out at 240 nm. The pH of the mobile phase was set at 3.0. Injection volume was 10 μl. The results of the optimized chromatographic condition are shown in Table 1.

Preparation of standard solution of RSV and FEN

For RSV, an accurately weighed 1.0 mg of RSV was transferred to a 10.0 ml volumetric flask and dissolved in 5.0 ml of diluent. The volume was completed to 10.0 ml with diluent. One milliliter of the resulting solution was pipetted in 10.0 ml volumetric flask and the volume was made up to 10.0 ml with diluent to furnish a solution of concentration 10 μg/ml of RSV.

For FEN, an accurately weighed 14.5 mg of FEN was transferred into six 10.0 ml volumetric flask and dissolved in 5.0 ml of diluent. The volume was completed to 10.0 ml with diluent. One milliliter of the resulting solution was pipetted in 10.0 ml volumetric flask and the volume was made up to 10.0 ml with diluent to furnish a solution of concentration 10 μg/ml and 145 μg/ml of RSV and FEN respectively.
Stress testing of drug substances can help to identify the likely degradation products, which can, in turn, help to work out the degradation pathways and thus the intrinsic stability of the drug substances. Specificity is the ability of the method to measure the responses of the analyte in the presence of its related substances. All stress degradation studies were performed at initial drug concentrations of 0.1 mg/ml for RSV and 1.45 mg/ml for FEN. Acid hydrolysis was performed in 0.1N HCl at 80°C for 24 hours. Alkali hydrolysis was performed in 0.1N NaOH at 80°C for 24 hours. Neutral hydrolysis was performed at 80°C for 24 hours. Oxidation studies were conducted at room temperature in 30% hydrogen peroxide for 24 hours. For photodegradation studies, the drug sample was exposed to sunlight for 30 days. Thermal hydrolysis was performed on the sand bath at 50°C for 24 hrs. Samples were withdrawn at appropriate times and subjected to HPLC analysis after suitable dilution to evaluate the ability of the proposed method to separate RSV and FEN from their degradation products.

System Suitability:
Specificity is the ability of the method to measure the responses of the analyte in the presence of its related substances. The suitability of the system was demonstrated by assessing various parameters. It was established by injecting six replicate injections of the standard solution. Theoretical plates were found to be 3636 and 4997, tailing factor of 1.30 and 1.45, and %RSD of peak area was 0.9 for both RSV and FEN respectively.

Linearity
Linearity test solutions of RSV and FEN were prepared at concentration levels of 6-16 µg/ml and 87-232 µg/ml respectively. Linearity test solutions were prepared by diluting the stock solution to the required concentrations. Linearity was established by the least-squares linear regression analysis of the calibration data. Peak areas were plotted against the respective concentrations and linear regression analysis performed on the resulting curves. The linearity curve for RSV and FEN was summarized by Fig. 3 and Fig. 4 respectively.

Precision
The system precision was evaluated by measuring the area of six qualified working standards for RSV and FEN calculating the percentage of relative standard deviation (RSD). The assay method precision was evaluated by conducting six independent assays of test samples of RSV and FEN against qualified working standards and calculating the percentage of relative standard deviation (RSD).

Accuracy
The accuracy of an analytical procedure expresses the closeness of agreement between the value, which is accepted either as a typical true value or an accepted reference value, and thus, the value found. It was computed at three different levels, i.e., 80, 100, and 120% of the label claim. Standard addition and recovery experiments were conducted to determine the accuracy of RSV and FEN for the quantification of drugs in the samples.

LOD and LOQ
The LOD is the lowest analyte concentration that can be detected. LOQ is the lowest analyte concentration that can be quantified with acceptable accuracy and precision. The limits of detection (LOD) and quantification (LOQ) were calculated from the standard deviation of the response and the slope of the calibration plot. LOD and LOQ were established, following ICH definitions, by use of the equations LOD = 3.3σ/S and LOQ = 10σ/S, where σ is the standard deviation of the regression line and S is the slope of the calibration plot.

Robustness
To evaluate the robustness of the developed method, the chromatographic conditions were deliberately altered and the resolution between RSV and FEN was evaluated. To study the effect of wavelength on the estimation, the wavelength was altered by ± 2 nm, i.e., 238 and 242 nm from the actual wavelength, 240 nm. To study the effect of flow rate on estimation, the flow rate was altered by ± 0.1 ml/min i.e., 0.9 and 1.1 ml/min from the actual flow rate, 1.0 ml/min.

RESULTS AND DISCUSSION
HPLC method development and optimization
Initially, pure drugs solution was chromatographed using a mobile phase consisting of a mixture of buffer (pH 3.0, adjusted with orthophosphoric acid) and acetonitrile in the ratio of (40:60) v/v at a flow rate of 1.0 ml/min. gives well-resolved peaks of drugs. Detection was carried out at 240 nm. The retention time under the optimized condition of rosuvastatin calcium and fenofibrate was found to be 2.485 min. & 3.905 min. respectively. The total run time of the chromatogram was about 20 minutes. A typical chromatograph of a mixture of standard and sample rosuvastatin calcium and fenofibrate is summarized by Fig. 5 and Fig. 6 respectively.

![Figure 3: Linearity curve of rosuvastatin calcium](image1)

![Figure 4: Linearity curve of fenofibrate](image2)
Validation of the method

System Suitability:
The suitability of the system was demonstrated by assessing various parameters. It was established by injecting six replicate injections of the standard solution. Theoretical plates were found to be 3636 and 4997, tailing factor of 1.30 and 1.45, and %RSD of peak area was 0.9 for both RSV and FEN respectively (Table 2). All the system suitability parameters were well within the limits, indicating that the system was well suitable for performing the analysis.

Table 2: System suitability results

| Parameter              | RSV  | FEN  |
|------------------------|------|------|
| Theoretical Plate      | 3636 | 4997 |
| Retention Time (Rt)    | 2.485| 3.905|
| Tailing factor         | 1.30 | 1.45 |
| Resolution             | 2.115| 6.874|
| % RSD                  | 0.9  | 0.9  |

Rt: Retention time, %RSD: Percentage relative standard deviation

Linearity

Linearity was established by the least-squares linear regression analysis of the calibration data. Calibration plots were linear over the concentration range of 6-16 µg/ml for RSV and 87-232 µg/ml for FEN. Peak areas were plotted against the respective concentrations and linear regression analysis performed on the resulting curves. The linear curve of rosuvastatin calcium and fenofibrate was shown in Fig. 3 and Fig. 4 respectively. The linear regression equation obtained was $Y=44776x+40116$ for RSV and $Y=415.83x+557.22$ for FEN with correlation coefficient 0.9999 and 0.9994 respectively. The results of linearity are shown in Table 3.

Table 3: Linearity results

| Parameter                | RSV  | FEN  |
|--------------------------|------|------|
| Concentration Range (µg/ml) | 6-16 | 87-232 |
| Slope (m)                | 44776| 415.83|
| Intercept                | 40116| 557.22|
| Coefficient correlation ($r^2$) | 0.9999 | 0.9994 |
Accuracy

Accuracy was computed by recoveries studies. The mean percentage recoveries values for three levels were found to be between 99.66-100.37% and 99.13-100.44% for RSV and FEN respectively. The percentage of recoveries values within the limits, indicating the method developed was accurate. The results of recovery are shown in Table 4.

| Drug | Level (%) | Amount taken (µg/ml) | Amount found* (µg/ml) | % Recovery* |
|------|-----------|----------------------|-----------------------|-------------|
| RSV  | 80        | 8                    | 7.99                  | 99.98       |
|      | 100       | 10                   | 9.96                  | 99.66       |
|      | 120       | 12                   | 12.04                 | 100.37      |
| FEN  | 80        | 116                  | 116.51                | 100.44      |
|      | 100       | 145                  | 143.74                | 99.13       |
|      | 120       | 174                  | 172.55                | 99.16       |

*Average of three determinations

Table 5: Robustness results

| Condition                          | RSV          | FEN          |
|------------------------------------|--------------|--------------|
|                                    | Amount estimated* [%] | RSD [%] | Amount estimated* [%] | RSD [%] |
| Change in wavelength (240±2 nm)    | 238 nm       | 97.28       | 0.5698 | 100.16       | 0.0900 |
|                                    | 242 nm       | 98.21       | 0.5733 | 100.08       | 0.1417 |
| Change in flow rate (1.0±0.1 ml/min) | 0.9 ml/min | 99.55       | 0.6381 | 99.37       | 0.2068 |
|                                    | 1.1 ml/min   | 99.24       | 0.5078 | 99.56       | 0.2009 |

*Average of three determinations, %RSD: Percentage relative standard deviation

Analysis of rosuvastatin calcium and fenofibrate from marketed tablets

The percentage assay of tablet formulation was found to be 98.69 and 99.96% for RSV and FEN respectively. The stability of the drug solutions was observed for 24 h. In degradation studies, the drug was exposed to various stress conditions. From the chromatograms of stressed samples, it was found that no interference from degradants was observed at the retention time of rosuvastatin calcium and fenofibrate. Optimum degradation was observed in the presence of acid and alkali. Substantial degradation was observed in the presence of water, light, and peroxide. No degradation was observed in the presence of peroxide and thermal for RSV and thermal for FEN. The results of the percentage of degradation are presented in Table 6 and Fig. 7-12. Hence, the method was found to be specific.
Fig. 7: Chromatogram of RSV and FEN degraded with acid hydrolysis

Fig. 8: Chromatogram of RSV and FEN degraded with alkali hydrolysis

Fig. 9: Chromatogram of mixture of RSV and FEN degraded with neutral hydrolysis

Fig. 10: Chromatogram of RSV and FEN degraded with oxidative hydrolysis
Fig. 11: Chromatogram of RSV and FEN degraded with exposed to direct sunlight

Fig. 12: Chromatogram of RSV and FEN degraded with thermal hydrolysis

Table 6: Stability-indicating method data for RSV and FEN

| Stress condition                        | RSV (% Degradation) | FEN (% Degradation) |
|-----------------------------------------|---------------------|---------------------|
| Acidic (0.1 N HCl for 24 hrs.)          | 10.06               | 9.29                |
| Alkaline (0.1 N NaOH for 24 hrs.)       | 12.96               | 8.72                |
| Hydrolytic (HPLC waters for 24 hrs.)   | 8.45                | 6.16                |
| Oxidative (30% H₂O₂ for 24 hrs.)       | No degradation      | 7.82                |
| Photo (Sunlight for 30 days)           | 6.21                | 1.45                |
| Thermal (Sand bath at 50°C for 24 hrs.)| No degradation      | No degradation      |

HPLC: High Performance Liquid Chromatography

Table 7: Summary of validation parameter

| Parameter                        | RSV                  | FEN                  |
|----------------------------------|----------------------|----------------------|
| Calibration range (µg/ml)        | 6-16                 | 87-232               |
| Optimized wavelength (nm)       | 240                  | 240                  |
| Retention Time                  | 2.485                | 3.905                |
| Regression equation (Y)         | Y = 44776x+40116     | Y = 415.83x+557.22   |
| Slope                           | 44776                | 415.83               |
| Intercept                       | 40116                | 557.22               |
| Coefficient correlation (r²)    | 0.9999               | 0.9994               |
| Precision (% RSD)               |                      |                      |
| Intraday                        | 0.9                  | 0.9                  |
| Interday                        | 0.6                  | 0.8                  |
| % Assay*                        | 98.69                | 99.96                |
| LOD (µg/ml)                     | 0.33                 | 16.51                |
| LOQ (µg/ml)                     | 1.00                 | 50.05                |

*Average of five determinations, LOD: Limit of detection, LOQ: Limit of quantification
CONCLUSION

The method enables simple, rapid, accurate, precise, specific, economical, and sensitive analysis of rosuvastatin calcium and fenofibrate in combined bulk and tablet dosage form. This method was validated following ICH guidelines. The method can, therefore, be used for routine quality control analysis rosuvastatin calcium and fenofibrate in bulk and tablet dosage form.

ACKNOWLEDGMENTS

The authors extend their sincere thanks to Cadila Pharmaceuticals Ltd, Ahmadabad (India), for providing gift sample of pure rosuvastatin calcium and fenofibrate. We also extend our thanks to the Head of Department, Department of Pharmaceutical Sciences RTM Nagpur University, Nagpur for providing the necessary facilities.

CONFLICT OF INTEREST STATEMENT

Authors declare that they have no conflict of interest exists in this investigation.

REFERENCES

1. The Merck Index, 13th Edn., Merck Research Laboratories, Merck & Co., White House Station, NJ, USA, 2004:3949.
2. P.D. Martin, M.J. Warwick, A.L. Dane, S.J. Hill, P.B. Giles, P.J. Phillips and E. Lenz. Clin Ther, 2003;25,2822.
3. Remington -The science and practice of pharmacy, 21st ed. Lippincott Williams & Wilkins, 2006:1368.
4. Sweetman SC. Martindale: The Complete Drug Reference. London, England, UK: Pharmaceutical Press, 2002.
5. Sever PS, Poultet NR, Dahlof B, Wewdwl H. Different Time Course for Prevention of coronary and Stroke Events by Atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial- Lipid – Lowering Arm. Amer J Cardio, 2005;96:39-44.
6. Pandya CP, Rajput SJ. Stress Degradation Studies of Riociguat, Development of Validated Stability Indicating Method, Identification, Isolation and Characterization of Degradation Products by LC-HR-MS/MS and NMR Studies. Ind J Pharm Edu and Res, 2019 Oct 1; 53(4):S630-41.
7. Bockhorn H, Hornung A, Hornung U, Schawaller D. Kinetic study on the thermal degradation of polypropylene and polyethylene. J Ana and Appl Pyro, 1999 Jan 1;48(2):93-109.
8. Shrimai C, Baghel M, Rajput S. Development and validation of stability indicating RP-HPLC method of naprafenc and its degradation products: application to degradation kinetic. Int J Pharm Pharm Sci, 2014;6(9):387-93.
9. Sailaja B, Srawan Kumar K. Stability-Indicating Method Development and Validation for The Estimation of Rosuvastatin Calcium in Bulkt and Tablet Formulation by Reverse-Phase High-Performance Liquid Chromatography. Asian J Pharm Clin Res, 2019;12:251-256.
10. Rajput P, Shah DB, Maheshwari DG. A review on chromatographic method for estimation of Rosuvastatin calcium. Int J Res Pharmacy Pharm Sci, 2018;3:28-31.
11. Thamema RK, Shitut NR, Pasikanti KK, Menon VCA, Venkata VPK, Mullangi R. Determination of Rosuvastatin in rat plasma by HPLC and its application to pharmacokinetic studies. Biomed Chromatogr, 2006;20:881-887.
12. Hassouna ME, Salem HO. Stability indicating new RP-HPLC method for the determination of rosuvastatin calcium in pure and tablets dosage forms. Int J Appl Pharm Bio Res, 2017;2:11-27.
13. Sirisha Mulukuri NV, Srinivasarao T, Raveendra BG. New RP-HPLC method development and validation for the estimation of rosuvastatin calcium in bulk drugs and formulations. J Pharm Res, 2017;11:257-260.
14. Hasumati AR, Rajput SJ, Dave JB, Patel CN. Development and validation of two chromatographic stability-indicating methods for determination of rosuvastatin in pure from and pharmaceutical preparation. Int J Chem Tech Res, 2009;1:677-689.
15. Kadav A, Vora DN. Stability indicating UPLC method for simultaneous determination of Atorvastatin calcium, Fenofibrate and their degradation products in Tablets, J Pharm and Biomed Ana. 2008;48:120-126.
16. Madala A, Keerthisikha P. A New Stability Indicating Method Development and Validation of RP-HPLC Method for the Simultaneous Estimation of Rosuvastatin Calcium and Fenofibrate in Tablet Dosage Form. Indo Amer J Pharm Sci, 2016;9:953-959.
17. Anusha, R, Geetha Susmita A, Rajitha G. Analytical Method Development and Validation of New RP-HPLC Method for Simultaneous Estimation of Brinzolamide and Timolol Maleate in Ophthalmic Solutions. Res J Pharm Bio Chem Sci, 2016;7(3):1290-1298.
18. ICH, Q1A, Stability Testing of New Drug Substances and Products, in: Proceedings of the International Conference on Harmonisation, Geneva, October, 1993.
19. Available from: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf.